"Revolution Medicines’ drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemotherapy, the company said Monday."
https://www.cnbc.com/2026/04/13/pancreatic-cancer-drug-daraxonrasib-from-revolution-medicines-succeeds-in-trial.html?user_id=66c4c92f5d78644b3ac5d5b4
No comments:
Post a Comment